Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Pharmacology

• Publication date

  1996-06-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0014-2999(96)00155-0PMID 8813526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine

  2005cited by this paper
• Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists

  2004cited by this paper
• Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats

  2004cited by this paper
• Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia

  2004cited by this paper
• The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat

  2004cited by this paper
• Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry.

  1995cited by this paper
• Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia

  1994cited by this paper
• Apolipoprotein E4 In Late Onset Depression

  1994cited by this paper
• Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment.

  1994cited by this paper
• Assessment of Striatal Extracellular Dopamine and Dopamine Metabolites by Microdialysis in Haloperidol-Treated Rats Exhibiting Oral Dyskinesia

  1993cited by this paper
• Amphetamine and Other Weak Bases Act to Promote Reverse Transport of Dopamine in Ventral Midbrain Neurons

  1993cited by this paper
• Regional differences in chronic neuroleptic effects on extracellular dopamine activity.

  1992cited by this paper
• Regional norepinephrine response to amphetamine using dialysis: Comparison with caudate dopamine

  1992cited by this paper
• Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.

  1992cited by this paper
• Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density

  1992cited by this paper
• Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats.

  1991cited by this paper
• Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride.

  1991cited by this paper
• Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.

  1991cited by this paper
• Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system.

  1991cited by this paper
• Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.

  1991cited by this paper
• Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size

  1990cited by this paper
• Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis.

  1990cited by this paper
• The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.

  1990cited by this paper
• Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies

  1989cited by this paper
• Advances in Neurology, vol 49: Facial Dyskinesias

  1989cited by this paper
• Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine.

  1989cited by this paper
• Paradoxical kinesia in parkinsonism is not caused by dopamine release. Studies in an animal model.

  1989cited by this paper
• Handbook of Psychopharmacology

  1988cited by this paper
• Tardive dyskinesia

  1988cited by this paper
• Amphetamine‐Induced Dopamine Release in the Rat Striatum: An In Vivo Microdialysis Study

  1988cited by this paper
• Adaptive changes in brain dopamine function as a result of neuroleptic treatment.

  1988cited by this paper
• Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.

  1988cited by this paper
• Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse

  1988cited by this paper
• Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.

  1987cited by this paper
• Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.

  1987cited by this paper
• The effects of footshock stress on regional brain dopamine metabolism and pituitary beta-endorphin release in rats previously sensitized to amphetamine.

  1987cited by this paper
• Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores.

  1986cited by this paper
• Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.

  1985cited by this paper
• Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine

  1985cited by this paper
• New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.

  1985cited by this paper
• The Reversibility of “Permanent” Tardive Dyskinesia

  1984cited by this paper
• The amphetamine paradox in dopaminergic neurotransmission

  1984cited by this paper
• Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis

  1984cited by this paper
• Neurobiological substrates of tardive dyskinesia: the GABA hypothesis

  1984cited by this paper
• History and Definition of Tardive Dyskinesia

  1983cited by this paper
• The prognosis of tardive dyskinesia.

  1983cited by this paper
• Therapeutic strategies against tardive dyskinesia. Two decades of experience.

  1982cited by this paper
• Effects of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation.

  1981cited by this paper
• Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

  1980cited by this paper
• Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs.

  1980cited by this paper
• Brain monoamines in the rhesus monkey during long-term neuroleptic administration.

  1980cited by this paper
• Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine.

  1979cited by this paper
• Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.

  1979cited by this paper
• Amphetamines: Biochemical and Behavioral Actions in Animals

  1978cited by this paper
• The release of endogenous norepinephrine and dopamine from cerebral cortex by amphetamine.

  1977cited by this paper
• Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

  1977cited by this paper
• Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.

  1974cited by this paper
• The pharmacology of tardive dyskinesias.

  1973cited by this paper
• Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.

  1972cited by this paper
• Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain.

  1971cited by this paper
• Enhanced stimulant effects of d-amphetamine on the spontaneous locomotor activity of rats treated with reserpine.

  1967cited by this paper
• ENHANCEMENT BY RESERPINE AND α-METHYL DOPA OF THE EFFECTS OF d-AMPHETAMINE UPON THE LOCOMOTOR ACTIVITY OF MICE

  1963cited by this paper
• EFFECTS OF ALPHA-METHYL DOPA AND DOPA ON THE AMPHETAMINE EXCITATORY RESPONSE IN RESERPINIZED RATS.

  1963cited by this paper
• Effects of α-Methyl DOPA and DOPA on the Amphetamine Excitatory Response in Reserpinized Rats

  1963cited by this paper
• Mechanism of action of cocaine and amphetamine in the brain

  1962cited by this paper

• PHYTOCHEMICAL ANALYSIS AND COMPARATIVE ANTIPARKINSON ACTIVITY OF FOUR SPECIES OF MUCUNA

  2018cites this paper
• Passiflora cincinnata Extract Delays the Development of Motor Signs and Prevents Dopaminergic Loss in a Mice Model of Parkinson's Disease

  2017cites this paper
• Assessment of Motor Function in Rodents: Behavioral Models Sharing Simplicity and Multifaceted Applicability

  2016cites this paper
• Rodent Model as Tools in Ethical Biomedical Research

  2016cites this paper
• Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats

  2016cites this paper
• NEUROPROTECTIVE EFFECT OF QUERCETIN IN NEUROTOXICITY INDUCED RATS: ROLE OF NEUROINFLAMMATION IN NEURODEGENERATION

  2014cites this paper
• Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia

  2011cites this paper
• Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats

  2007cites this paper
• Effects of baclofen on reserpine-induced vacuous chewing movements in mice.

  2006cites this paper
• Effect of Withania somnifera root extract on reserpine‐induced orofacial dyskinesia and cognitive dysfunction

  2006cites this paper
• Effects of diphenyl-diselenide on orofacial dyskinesia model in rats.

  2006cites this paper
• Effects of gabaergic drugs on reserpine-induced oral dyskinesia.

  2005cites this paper
• Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity.

  2005cites this paper
• Effects of social isolation on aging-induced orofacial movements in rats.

  2005cites this paper
• Effects of topiramate on oral dyskinesia induced by reserpine.

  2004cites this paper
• Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia.

  2004cites this paper
• Reversal of Reserpine-Induced Orofacial Dyskinesia and Cognitive Dysfunction by Quercetin

  2004cites this paper
• Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.

  2003cites this paper
• Effects of valproic acid on an animal model of tardive dyskinesia.

  2003cites this paper
• EFFECTS OF BUSF ’ IRONE ON AN ANIMAL MODEL OF TARDIVE DYSKINESIA

  2003influential citation
• Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats.

  2003cites this paper
• Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum.

  2003cites this paper
• Effects of melatonin on orofacial movements in rats

  2002cites this paper
• The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats.

  2002cites this paper
• Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice.

  2002cites this paper
• Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats.

  1998cites this paper
• Acute reserpine administration elicits long-term spontaneous oral dyskinesia.

  1997cites this paper